Connect with us

Business

Chancellor abandons planned income tax hike because of improved forecasts

Published

on

Chancellor abandons planned income tax hike because of improved forecasts



The Chancellor has abandoned plans to hike income tax at the Budget because of improved economic forecasting.

Rachel Reeves had been expected to hike income tax in the face of a yawning gap in her spending plans, hinting as recently as Monday that the alternative would be “deep cuts” to public investment.

But reporting overnight claimed she has abandoned introducing an income tax rise at the November 26 Budget over fears it could anger both voters and backbench Labour MPs.

The PA news agency understands the strength of tax receipts has improved forecasting from the Office for Budget Responsibility, allowing for the U-turn.

This is particularly the case on stronger wage performance: the higher wages are, the more tax is paid on them.

A downgrade in productivity has also not been as bad as was first feared.

While Ms Reeves is no longer understood to be pursuing an income tax hike, tough choices are still said to lie ahead for the Government and other tax rises have not been ruled out.

Income tax thresholds could still be reduced while tax rates are kept the same, a move which could raise billions of pounds for the Treasury.

Limits to salary sacrifice schemes, as well as new measures to tax electric vehicles, are still in the mix as the Treasury pursues a “smorgasbord” approach of raising a range of smaller taxes.

The Chancellor has not changed her approach, it is understood, and still intends to give herself larger fiscal headroom – the buffer against economic headwinds which could impact Government spending plans.

The latest Budget measures were submitted last week, rather than being a knee-jerk response to the turmoil in No 10 this week sparked by a briefing war.

Ms Reeves has been laying the ground for tax rises over recent weeks, including during an early-morning speech on November 4 aimed at preparing the public for the Budget.

Downing Street insisted that the thrust of the speech “stands”.

The Prime Minister’s official spokesman said: “She was very clear about the challenges the country faces and her priorities in addressing those challenges.

“All of that still stands.”

The spokesman refused to comment on Budget speculation, but said the Chancellor will aim to “build more resilient public finances with the headroom to withstand global turbulence”.

This would “give businesses the confidence to invest and leaving the Government freer to act when the situation calls for it”, he added.

Government borrowing costs rose in the wake of the apparent U-turn on income tax on Friday morning.

Speculation about the change in direction sparked a sell-off in UK Government bonds, also known as gilts: the means by which the Government borrows money from private investors.

The gilt market later stabilised somewhat as the reasoning behind the Treasury’s decision-making became apparent.

Among those who welcomed suggestions the tax rise had been abandoned was Health Secretary Wes Streeting.

He told PA: “What I would say about this morning is, it is really important that we keep the promises that we made to the public at the last general election.

“Our economy was broken by the Conservatives, so were our public services, but so was trust in politics itself.

“Our job is to rebuild the economy, rebuild our public services, and rebuild trust in politics.”

Helen Miller, director of the Institute for Fiscal Studies (IFS) think tank, said it was “not unusual” for chancellors to make last-minute changes to their Budget plans.

She added: “But the news that Rachel Reeves has backed away from a plan to increase the rates of income tax will lead investors to worry that the Chancellor will instead increase a range of smaller taxes that can be more damaging to economic growth.

“They may also worry that the change of plans signals that this Government are reluctant to do politically difficult things.

“These are the kinds of concerns that can lead investors to demand higher returns when lending to the Government.”

If the Government does choose to raise a set of smaller taxes, they should also be reformed “so that they do less damage to growth”, the IFS chief said.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

FDA chief Marty Makary says ‘everything should be over the counter’ unless drug is unsafe or addictive

Published

on

FDA chief Marty Makary says ‘everything should be over the counter’ unless drug is unsafe or addictive


Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over the counter” unless a drug is unsafe, addictive or requires monitoring – doubling down on a push that some in the pharmaceutical industry have questioned

In an interview Wednesday in Washington, D.C., Makary said the FDA aims to make changes this year that allow more companies to offer their prescription medicines over the counter, or OTC. He noted that the agency is going through “the proper regulatory processes” to update OTC monographs –  the rulebooks that determine which drugs can be sold without a prescription. 

Makary said the FDA is looking at “basic, safe” prescription drugs like nausea medications and vaginal estrogen, which is used to treat menopausal symptoms like dryness and pain. 

“In my opinion, everything should be over the counter and not requiring a prescription, unless it’s unsafe, unless you need laboratory tests to monitor how it’s being received by your body, or if it could be used for some nefarious purpose or it’s addictive,” Makary told CNBC after the PhRMA Forum, a one-day event organized by the pharmaceutical industry’s largest lobbying group. 

“If it doesn’t meet those criteria, why shouldn’t a drug be over the counter? So we should be asking, why not? Instead of, ‘Oh, you want to move over the counter, you got to go through a long, tedious process,'” he added. 

Marty Makary, U.S. President Donald Trump’s nominee to be U.S. Food and Drug Administration (FDA) commissioner, testifies before a Health, Education, Labor, and Pensions (HELP) Senate Committee confirmation hearing on Capitol Hill in Washington, D.C., U.S., March 6, 2025. 

Kent Nishimura | Reuters

The FDA has long considered making some prescription drugs available OTC to improve accessibility, reduce health-care costs and help patients stay on their medications. For example, patients wouldn’t have to take time off work to see a doctor for a prescription or could refill a drug without delay.

Congress boosted the effort through legislation in November that streamlines the regulatory process for prescription-to-OTC transitions, including full, conditional and partial “switch” pathways.

Makary framed the FDA’s latest push to expand OTC access as another way to lower drug costs, a key priority of the Trump administration. He argued that placing medications directly on store shelves would bypass insurers and pharmacy benefit managers, eliminating the rebate-driven system that often obscures a drug’s true price.

He also said selling drugs over the counter promotes transparency that “keeps prices in check.” In some cases, Makary said cash prices for OTC medicines are lower than patients’ copays for prescription drugs “when there’s a money game going on behind the pharmacy counter,” with employers and insurers sharing the cost.

Pharma questions OTC push

Some in the pharmaceutical industry have pushed back on that argument. Most OTC drugs are not covered by insurance, meaning their prices could eclipse those of generic prescription medicines and potentially make them less affordable for patients who rely on coverage. 

In comments to the FDA earlier this month, the Association for Accessible Medicines argued that “the shift of many prescription drugs to nonprescription status could actually increase costs to patients, thereby decreasing patient access to treatments.” That organization represents manufacturers and distributors of generic prescription medicines. 

The FDA also doesn’t have the authority to regulate drug prices. In its own comments this month, PhRMA said the agency must respect “the core principle that pricing considerations may not factor into FDA regulatory decision-making.”

More CNBC health coverage

The Pharmaceutical Research and Manufacturers of America added that the FDA should not attempt to transition any prescription drugs to OTC without first consulting manufacturers. But the group emphasized that it supports the FDA’s effort to expand access to crucial medicines. 

In its own comment this month, AstraZeneca said several previous attempts to transition cholesterol-cutting statins to OTC status have been “unsuccessful, with consumers consistently having difficulty making proper self-selection decisions.” 

Meanwhile, Makary told CNBC on Wednesday that “we have to trust people to make their decisions. We’ve got to get away from this paternalistic mindset.”

The FDA removed the longtime director of the office of over-the-counter drugs, Theresa Michele, from her position in December, STAT news reported at the time. 



Source link

Continue Reading

Business

Stock market today: Which are top gainers and losers on NSE and BSE on February 18? Check list – The Times of India

Published

on

Stock market today: Which are top gainers and losers on NSE and BSE on February 18? Check list – The Times of India


Market ended in green for the third straight session on Wednesday, with benchmark equity indices rising on the back of last-hour buying in banking, metal and FMCG stocks.The 30-share BSE Sensex jumped 283.29 points, or 0.34 per cent, to settle at 83,734.25 in a volatile trade. The 50-share NSE Nifty gained 93.95 points, or 0.37 per cent, to close at 25,819.35.Among the Sensex constituents, Tata Steel, ITC and Kwality Walls were the major gainers. On the other hand, Eternal, Tech Mahindra and Infosys were the laggards.“Indian markets witnessed a late surge driven by broad-based buying after a cautious start, as positive domestic sectoral cues helped offset lingering global uncertainties,” Vinod Nair, Head of Research, Geojit Investments Ltd, said.He added that banking and financial stocks remained resilient on the back of steady asset-quality expectations, while selective buying in FMCG names contributed to relative outperformance.Broader indices also traded firm, with the BSE Smallcap Select Index rising 1.02 per cent and the Midcap Select Index gaining 0.40 per cent.“Indian equity markets extended gains for the third consecutive session staging a gradual recovery, with the Nifty rising 0.4 per cent, supported by strength in PSU and metal stocks. On the flows front, FIIs remained net buyers on Tuesday, purchasing equities worth Rs 995 crore, while DIIs also bought shares worth Rs 187 crore, providing support to sentiment,” Siddhartha Khemka, Head of Research, Wealth Management, Motilal Oswal Financial Services Ltd, said.

Nifty50 top gainers

Company Name Current Price (Rs) Price Change % Change
Kwality Wall’s 29.33 1.38 ↑ 4.94% ↑
HDFC Life 729.60 23.80 ↑ 3.38% ↑
Tata Steel 209.03 5.95 ↑ 2.93% ↑
ITC 332.45 7.00 ↑ 2.16% ↑
Tata Consumer 1,170 21.20 ↑ 1.85% ↑
Bajaj Auto 9,980 154.00 ↑ 1.57% ↑
Axis Bank 1,377 19.80 ↑ 1.46% ↑
Reliance Industries 1,441 18.30 ↑ 1.29% ↑
Nestle India 1,301 15.60 ↑ 1.22% ↑
M&M 3,531 41.30 ↑ 1.19% ↑

Nifty50 top losers

Company Name Current Price (Rs) Price Change % Change
ONGC 264.60 -7.25 ↓ -2.67% ↓
Wipro 211.95 -3.75 ↓ -1.74% ↓
Eternal 277.35 -4.15 ↓ -1.48% ↓
Adani Enterprises 2,211 -31.71 ↓ -1.42% ↓
Infosys 1,374 -17.50 ↓ -1.26% ↓
Tech Mahindra 1,505 -19.00 ↓ -1.25% ↓
HCL Technologies 1,467 -15.40 ↓ -1.04% ↓
Adani Ports & SEZ 1,551 -15.50 ↓ -0.99% ↓
Coal India 418.00 -3.56 ↓ -0.85% ↓
TCS 2,695 -22.50 ↓ -0.83% ↓

Sensex top gainers

Company Name Current Price (Rs) Price Change % Change
Kwality Wall’s 29.33 1.38 ↑ 4.94% ↑
Tata Steel 209.03 5.95 ↑ 2.93% ↑
ITC 332.45 7.00 ↑ 2.16% ↑
Axis Bank 1,377 19.80 ↑ 1.46% ↑
Reliance Industries 1,441 18.30 ↑ 1.29% ↑
M&M 3,531 41.30 ↑ 1.19% ↑
Larsen & Toubro 4,326 46.10 ↑ 1.08% ↑
Bajaj Finance 1,024 9.65 ↑ 0.96% ↑
Bajaj Finserv 2,061 16.20 ↑ 0.80% ↑
UltraTech Cement 13,052 68.00 ↑ 0.53% ↑

Sensex top losers

Company Name Current Price (Rs) Price Change % Change
Eternal 277.35 -4.15 ↓ -1.48% ↓
Infosys 1,374 -17.50 ↓ -1.26% ↓
Tech Mahindra 1,505 -19.00 ↓ -1.25% ↓
HCL Technologies 1,467 -15.40 ↓ -1.04% ↓
Adani Ports & SEZ 1,551 -15.50 ↓ -0.99% ↓
TCS 2,695 -22.50 ↓ -0.83% ↓
Asian Paints 2,432 -5.31 ↓ -0.22% ↓
NTPC 368.00 -0.40 ↓ -0.11% ↓
HDFC Bank 924.70 -1.00 ↓ -0.11% ↓
Maruti Suzuki 15,164 -15.00 ↓ -0.10% ↓

In Asian markets, Japan’s Nikkei 225 benchmark closed 1 per cent higher, while markets in China, Hong Kong and South Korea remained closed due to Lunar New Year holidays. European markets were trading higher in mid-session deals, and US equities had settled in positive territory on Tuesday.Foreign institutional investors bought equities worth Rs 995.21 crore on Tuesday, while domestic institutional investors purchased stocks worth Rs 187.04 crore, according to exchange data. Brent crude, the global oil benchmark, rose 0.33 per cent to USD 67.64 per barrel.(Disclaimer: Recommendations and views on the stock market, other asset classes or personal finance management tips given by experts are their own. These opinions do not represent the views of The Times of India)



Source link

Continue Reading

Business

Barry nurse who overpaid thousands in income tax issues warning to others

Published

on

Barry nurse who overpaid thousands in income tax issues warning to others


Belby, a district nurse, had hoped to get the money returned in time for Christmas but found the process of trying to secure her refund slow and stressful, especially because she said she was given conflicting information and was quoted two vastly different figures of how much she was owed.



Source link

Continue Reading

Trending